These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27637383)

  • 1. Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect.
    Sly PD; Varghese J; Noor F; Tang ML; Laing I; Oo S; Prastanti F; LeSouef PN; Holt PG
    J Allergy Clin Immunol; 2017 Feb; 139(2):703-705.e4. PubMed ID: 27637383
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Teramoto T; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2017 Jan; 66(1):106-115. PubMed ID: 27507228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
    Zazzali JL; Raimundo KP; Trzaskoma B; Rosén KE; Schatz M
    Allergy Asthma Proc; 2015; 36(4):283-92. PubMed ID: 26108086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.
    Esquivel A; Busse WW; Calatroni A; Togias AG; Grindle KG; Bochkov YA; Gruchalla RS; Kattan M; Kercsmar CM; Khurana Hershey G; Kim H; Lebeau P; Liu AH; Szefler SJ; Teach SJ; West JB; Wildfire J; Pongracic JA; Gern JE
    Am J Respir Crit Care Med; 2017 Oct; 196(8):985-992. PubMed ID: 28608756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.
    Kupryś-Lipińska I; Majak P; Molinska J; Kuna P
    BMC Pulm Med; 2016 Apr; 16(1):61. PubMed ID: 27117315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
    Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
    J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.
    Gibson PG; Reddel H; McDonald VM; Marks G; Jenkins C; Gillman A; Upham J; Sutherland M; Rimmer J; Thien F; Katsoulotos GP; Cook M; Yang I; Katelaris C; Bowler S; Langton D; Robinson P; Wright C; Yozghatlian V; Burgess S; Sivakumaran P; Jaffe A; Bowden J; Wark PA; Yan KY; Kritikos V; Peters M; Hew M; Aminazad A; Bint M; Guo M
    Intern Med J; 2016 Sep; 46(9):1054-62. PubMed ID: 27350385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study.
    Cusack RP; Sahadevan A; Lane SJ
    QJM; 2016 Sep; 109(9):601-4. PubMed ID: 26966102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.
    Sposato B; Scalese M; Latorre M; Scichilone N; Matucci A; Milanese M; Masieri S; Rolla G; Steinhilber G; Rosati Y; Vultaggio A; Folletti I; Baglioni S; Bargagli E; Di Tomassi M; Pio R; Pio A; Maccari U; Maggiorelli C; Migliorini MG; Vignale L; Pulerà N; Carpagnano GE; Foschino Barbaro MP; Perrella A; Paggiaro PL
    Respir Med; 2016 Oct; 119():141-149. PubMed ID: 27692136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of long-term omalizumab therapy in patients with severe asthma.
    Saji J; Yamamoto T; Arai M; Mineshita M; Miyazawa T
    Respir Investig; 2017 Mar; 55(2):114-120. PubMed ID: 28274526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
    Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
    Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.
    Hew M; Gillman A; Sutherland M; Wark P; Bowden J; Guo M; Reddel HK; Jenkins C; Marks GB; Thien F; Rimmer J; Katsoulotos GP; Cook M; Yang I; Katelaris C; Bowler S; Langton D; Wright C; Bint M; Yozghatlian V; Burgess S; Sivakumaran P; Yan KY; Kritikos V; Peters M; Baraket M; Aminazad A; Robinson P; Jaffe A; Powell H; Upham JW; McDonald VM; Gibson PG
    Clin Exp Allergy; 2016 Nov; 46(11):1407-1415. PubMed ID: 27377155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy.
    Novelli F; Latorre M; Vergura L; Caiaffa MF; Camiciottoli G; Guarnieri G; Matucci A; Macchia L; Vianello A; Vultaggio A; Celi A; Cazzola M; Paggiaro P;
    Pulm Pharmacol Ther; 2015 Apr; 31():123-9. PubMed ID: 25281265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.
    Luu M; Bardou M; Bonniaud P; Goirand F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1503-1511. PubMed ID: 27748630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe uncontrolled asthma in patients over 75 years old: Treatment with omalizumab].
    Romand P; Kelkel E; Saint-Raymond C; Glas N; Caillaud D; Devouassoux G
    Rev Mal Respir; 2016 May; 33(5):397-400. PubMed ID: 26346416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.